All In Biotech

Drug Trial Radar · NCT00418171

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

An International, Multicenter, Large Simple Trial (LST) To Compare The Cardiovascular Safety Of Ziprasidone And Olanzapine

Last checked: Nov 19, 2026Latest source record: Oct 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 18,239 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18,239

Actual

Start

Feb 2002

Primary completion

Not stated

Study completion Apr 2007

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 4, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.

Conditions

  • Schizophrenia

Interventions

  • ZiprasidoneDrug

  • OlanzapineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality within 12 months.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    San Bernardino, California

  • Pfizer Investigational Site

    ‘Aiea, Hawaii

  • Pfizer Investigational Site

    Schaumburg, Illinois

  • Pfizer Investigational Site

    Grants Pass, Oregon

  • Pfizer Investigational Site

    White Hall, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.